BLOG

Japan’s Regenerative Medicine Law and Stem Cell Therapy in Osaka

7 min read

Hello, I am Dr. Hidenori Shimada of Grand Green Osaka Umekita Clinic in Osaka, Japan.

If you are researching stem cell therapy in Japan, you will often see references to a national law governing regenerative medicine. For international patients, this can sound abstract. What does it actually cover, and how does it relate to the treatment you may be considering? This article explains the general framework in plain language and suggests questions to bring to a consultation at Grand Green Osaka Umekita Clinic in Osaka.

The short answer

In Japan, regenerative medicine that uses cells, including cultured mesenchymal stem cells taken from a person’s own fat tissue, is handled under a specific legal framework. Clinics that offer such treatment as self-pay medicine are expected to follow a defined process, including a treatment plan that is reviewed before it is used with patients. The law does not tell you whether a particular treatment will suit you, and it does not promise any outcome. Whether adipose-derived stem cell therapy is appropriate for you, what it may cost, and what risks it carries are matters to confirm with a physician at a consultation.

Why a separate law exists for cell-based treatment

Regenerative medicine covers a wide range of approaches, from cells grown in a laboratory to tissues prepared for transplantation. Because these products are living cells rather than conventional drugs, the way they are collected, processed, cultured, and administered matters a great deal. Japan introduced the Act on the Safety of Regenerative Medicine so that clinics providing these therapies work within common rules, rather than each deciding its own standards.

In general terms, the framework classifies regenerative treatments by their level of risk and sets out procedures for each class. It asks providers to prepare a plan describing the treatment, the facilities involved, and how patients will be informed. Official explanations are published by the Ministry of Health, Labour and Welfare, and the details can change over time, so it is worth treating any summary, including this one, as a starting point rather than a final reference.

How this applies to adipose-derived stem cell therapy

Adipose-derived stem cell therapy at Grand Green Osaka Umekita Clinic follows a two-step flow. A very small amount of your own fat tissue is collected under local anesthesia. The mesenchymal stem cells it contains are then cultured and expanded at a specialized facility, and the cells are later returned to your body by intravenous infusion. Both steps are done on an outpatient basis.

Each part of that flow, from collection to culture to infusion, falls within the scope of the regenerative medicine framework. The clinic provides this treatment under a regenerative medicine provision plan. If you want to understand what that means in practice, you can ask the clinic which plan applies to your treatment and how it is managed, and you can request an explanation in a language you are comfortable with.

What the law does not decide for you

It is easy to assume that a regulated treatment is automatically right for any patient. That is not how the framework works. Several important points remain individual and need a doctor’s judgment.

  • Whether you are a suitable candidate, which depends on your medical history and current health.
  • What benefits, if any, you might reasonably expect. Research on mesenchymal stem cells is active but still developing, and results vary between studies and between individuals.
  • The possible risks and side effects, including those related to fat collection and intravenous infusion.
  • How this option fits alongside standard medical care you may already be receiving. Stem cell therapy should not be understood as a replacement for standard treatment.

The treatment is also self-pay, meaning it is not covered by public health insurance. Fees, the number of sessions, and the overall schedule should be confirmed in writing at the consultation, before you decide anything.

Questions international patients can ask before treatment

Medical travel adds practical layers, such as language, distance, and follow-up after you return home. These questions can help you prepare for a productive conversation.

  • Which regenerative medicine plan covers this treatment, and can I receive an explanation of its scope?
  • Where are the cells cultured, and how is the process managed and documented?
  • What are the known risks, side effects, and limitations for someone with my background?
  • What does the full cost include, and are there additional charges for tests, travel between the two visits, or follow-up?
  • How will my records be shared with my doctor at home, and who can I contact if I have concerns after I leave Japan?
  • Are there conditions or medications that could make this treatment unsuitable for me?

Bringing your medical records, a list of current medications, and notes on your goals will help the physician give you a more accurate picture. A written summary in English can also make it easier to discuss the plan with your regular doctor.

Planning your consultation in Osaka

Grand Green Osaka Umekita Clinic is located in the Umeda area of Osaka, which is convenient to reach from Kansai International Airport and from major rail lines. The clinic provides an information page for international patients, and you can use it to learn about the process and to arrange an initial discussion in advance. Starting with a consultation gives you time to ask about the legal framework, the treatment steps, the fees, and the risks, without any obligation to proceed.

Because the treatment involves two stages, with cell culture taking place between them, it is sensible to talk through the timeline early. A physician can explain how the schedule might look in your case and whether it fits with your travel plans.

Summary

Japan regulates cell-based treatment through a dedicated framework, and adipose-derived stem cell therapy at Grand Green Osaka Umekita Clinic is provided under a regenerative medicine provision plan as a self-pay treatment. That framework sets the rules providers follow, but it does not determine whether the therapy is right for you or what result you might see. Those questions, along with fees, risks, and side effects, need to be reviewed with a physician in a consultation. Preparing your records and a short list of questions beforehand can help you make an informed and unhurried decision.

References

Supervising Physician

Hidenori Shimada

Director, Medical Corporation Shimada Clinic
Head of Clinical Practice, Grand Green Osaka Umekita Clinic

Hidenori Shimada

Graduated from the University of Tokushima Faculty of Medicine in 2005. After his initial residency, he obtained U.S. medical certification (ECFMG) and trained as a sub-intern in general surgery at the University of Washington. After completing the doctoral program at Kyoto University Graduate School of Medicine and working as a researcher at the Center for iPS Cell Research and Application (CiRA), Kyoto University, he founded Shimada Clinic in 2013. At Grand Green Osaka Umekita Clinic (https://umekitaclinic.org), he is engaged in a wide range of care, from internal medicine and pediatrics to cell therapy and aesthetic medicine.

* The physician supervision of this article covers its academic content only and does not constitute a recommendation of any specific treatment or product.

Grand Green Osaka South Building, Gate Tower 5F 5-54 Ofuka-cho, Kita-ku, Osaka 530-0011, Japan

TEL: 06-7653-8493 FAX: 06-7635-8052

Contact